NEW YORK & FORT MILL, S.C.–(BUSINESS WIRE)–Lash Group, a patient support services company and a part of
AmerisourceBergen, and AllazoHealth, an artificial intelligence (AI) and
predictive analytics company focused on ensuring optimal patient
outcomes, today announced a partnership that will enhance patient
adherence and engagement programs through targeted and personalized
recommendations that will empower at-risk patients to ultimately make
Studies have shown that medication nonadherence can be caused by a mix
of situational and behavioral barriers that are unique to each patient
and their health journey. With the use of AllazoHealth’s proprietary
AllazoEngine, which precisely identifies at-risk patients through
predictive analytics, Lash Group will be the first HUB services provider
to leverage individualized patient predicted risk along with machine
learning to provide personalized interventions that are unique to
behaviors and treatment plans.
“At Lash Group, we are committed to providing the right blend of
high-technology and high-touch services that drive patient engagement
and ultimately improve the patient healthcare journey. By coupling an
innovative technology solution, like the AllazoEngine, with Lash Group’s
existing team of accredited, high-quality counselors and clinicians, we
can offer our partners an advanced solution that will reduce barriers to
treatment, increase access and enhance health outcomes,” said Tommy
Bramley, President of Lash Group.
As part of its patient adherence and engagement offerings, Lash Group
will leverage the AllazoEngine to recommend a specific cadence and
intervention type through methods such as motivational text messages to
patients, targeted touchpoints made by a clinician, or simple reminders
delivered through our multi-channel services. The ability to correlate
specific patient behavior with predictive risk allows Lash Group to
adjust its communication style with each patient and recommend the most
appropriate interventions within the care map.
The AllazoEngine is the only AI platform with effectiveness validated
through peer-reviewed Randomized Control Trial (RCT). In fact, according
to the RCT, the AllazoEngine was proven to achieve a 5.5x greater
adherence uplift compared to traditional programs.
“We are pleased to be joining forces with Lash Group to provide better,
more personalized support for patients of all types, and are excited by
the opportunity to support Lash Group’s patients as part of their
adherence programs,” said Clifford Jones, CEO of AllazoHealth.
AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
21,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500,
with more than $160 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at amerisourcebergen.com.
AllazoHealth is a machine learning company that focuses on driving the
behavioral change of patients through personalized and proactive
intervention. Our mission is to be the leader in precision engagement &
predictive analytics, revolutionizing the way our enterprise healthcare
clients engage and improve the health of their patient population. For
more information about AllazoHealth – https://allazohealth.com/